| Fei Xu,Xiaoli Ren,Yuan Chen,Qianxia Li,Ruichao Li,Yu Chen,Shu Xia. Progress in the diagnosis and treatment of extensive-stage small cell lung cancer. Oncol Transl Med, 2019, 5: 33-42. |
| Progress in the diagnosis and treatment of extensive-stage small cell lung cancer |
| Received:December 11, 2018 Revised:March 03, 2019 |
| View Full Text View/Add Comment Download reader |
| KeyWord:small cell lung cancer (SCLC); extensive-stage; targeted therapy; immunotherapy |
| Author Name | Affiliation | E-mail | | Fei Xu | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | 15172501812@163.com | | Xiaoli Ren | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Yuan Chen | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Qianxia Li | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Ruichao Li | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Yu Chen | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Shu Xia | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | xiashutj@hotmail.com |
|
| Hits: 6305 |
| Download times: 8724 |
| Abstract: |
| Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant
tumors globally each year. Small cell lung cancer (SCLC) accounts for approximately 15% of newly
diagnosed lung cancers each year, but its annual death toll accounts for 25% of that of lung cancer. We
summarized relevant clinical studies to elaborate the epidemiology, pathological and clinical characteristics
and the treatment status of small cell lung cancer. This paper first described the epidemiology and the
pathological and clinical characteristics of SCLC and the systematic treatment of extensive-stage SCLC
and then introduced the current targeted therapy and immunotherapy for SCLC to provide clinicians and
patients with a more systematic, comprehensive, and beneficial treatment regimen. We expect that these
studies can provide clinicians with a clear direction in molecularly targeted therapy or immunotherapy, so
that a treatment approach with better antitumor effects and longer-lasting clinical benefits can be provided
to the patients. |
| Close |
|
|
|